Human IL8 Recombinant Protein (HEK293 Expression) — Tag Free
Price range: $150.00 through $2,980.00
HEK293 × Chaperone-Assisted Technology
Produced using our proprietary Z-Active® platform — HEK293 mammalian expression with chaperone-assisted folding for proper disulfide bonding, N-linked glycosylation, and 5–10× higher bioactivity vs Leading Suppliers.
Overview
Interleukin-8 (IL-8), also known as CXCL8, GCP-1, and NAP-1, is a widely expressed proinflammatory member of the CXC family of chemokines. Near its N-terminus, this 8-9 kDa chemokine contains an ELR motif which is important for its angiogenic properties (1). IL-8/CXCL8 can associate into a homodimer or a heterodimer with CXCL4/PF4 (2), and it can also interact with matrix and cell surface glycosaminoglycans (3). Mature human IL-8/CXCL8 shares 65%-69% amino acid (aa) sequence identiity with canine, feline, and porcine IL-8/CXCL8 (4). There is no IL-8/CXCL8 gene counterpart in rodent. N-terminal truncation by multiple proteases generates a range of shorter forms, and an alternative splice form of human IL-8/CXCL8 carries an eleven aa substitution at the C-terminus (5). The bioactivity of IL-8/CXCL8 is regulated by these truncations, by IL-8/CXCL8 citrullination at Arg5 (N-terminal to the ELR motif) (6), and by the decoy receptor DARC (7). IL-8/CXCL8 effects are mediated through CXCR1/IL-8 RA, which is also used by CXCL6, and through CXCR2/IL-8 RB, which is used by multiple CXC chemokines (1). CXCR1 and CXCR2 associate into functional homodimers and heterodimers with each other (8). Through both CXCR1 and CXCR2, CXCL8 promotes neutrophil adhesion to the vascular endothelium and migration to sites of inflammation (9). It triggers the antimicrobial activation of neutrophils through CXCR1 (10). CXCL8 also binds to Serpin A1/alpha-1 Antitrypsin, and this prevents IL-8/CXCL8 interaction with CXCR1 (11). IL-8/CXCL8 is upregulated in atherosclerotic lesions and other cardiac pathologies where it exacerbates inflammatory tissue damage (12). In addition, it induces VEGF expression, vascular endothelial cell proliferation, angiogenesis, and tumor cell invasiveness (13-16).
Specifications
- Species: human
- Expression System: HEK293
- Sequence: Ser28-Ser99
- Tag: Tag Free
- Molecular Weight: 8.4 KDa
- Purity: > 95% by Tris-Bis PAGE;> 95% by SEC-HPLC
- Endotoxin: < 1 EU/μg of the protein by LAL method.
- UniProt/Swiss-Prot: P10145
- Available Sizes: 10 µg, 50 µg, 1 mg
Bioactivity
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CXCR2. The ED50 for this effect is 0.5-2.5 ng/mL.
Formulation & Reconstitution
Formulation: 0.22 μm filtered solution of PBS, pH 7.4.
Reconstitution: 0.2 mg/mL in sterile PBS, pH7.4
Storage & Stability
Aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.
Quality Assurance
Each lot is tested for purity (SDS-PAGE, SEC-HPLC), endotoxin levels (LAL method), and bioactivity. A Certificate of Analysis (COA) is provided with every order.
Safety Data Sheets & Documentation
Protocols & Support
Reconstitution Protocol
1. Briefly centrifuge the vial to collect lyophilized powder at the bottom.
2. Reconstitute in sterile deionized water or PBS to a concentration of 0.2–1.0 mg/mL.
3. Gently pipette up and down to dissolve. Do not vortex.
4. Aliquot and store at -20°C to -80°C. Avoid repeated freeze-thaw cycles.
Download Data Sheet
Complete product data sheet including batch-specific QC data, sequence information, and storage guidelines.
Download PDF Data Sheet
